Clinical Trial Update: Immunotherapy With TG4040 in Treatment-naïve Patients Chronically Infected With Hepatitis C Virus [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 trial of TG4040 immunotherapy in treatment-naïve patients chronically infected with hepatitis C virus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• TG4040

Snippet

Sponsor: Transgene | Conditions: Hepatitis C, Chronic | Phase 1 | Status: COMPLETED